Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

NCT00372073 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

187

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: seliciclib
DRUG: placebo

Sponsor

Cyclacel Pharmaceuticals, Inc.